TKT Regains European Rights to Dynepo

Law360, New York (March 26, 2004, 12:00 AM EST) -- French drug maker Aventis has returned rights to Transkaryotic Therapies for the anemia treatment Dynepo, which the companies have been unable to market because of a long-running patent dispute with biotech rival Amgen.

Under the revised agreement, TKT will pay Aventis a scaled royalty on Dynepo sales for the right to market the drug in all territories outside the U.S.

Aventis will retain rights to commercialize Dynepo in the U.S. under essentially the same terms as the original agreement and has obtained an option on certain...
To view the full article, register now.